



- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2024/032660
- (22) **International Filing Date:**
05 June 2024 (05.06.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/506,177 05 June 2023 (05.06.2023) US
63/611,302 18 December 2023 (18.12.2023) US
- (71) **Applicant:** LIFORDI IMMUNOTHERAPEUTICS, INC. [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US).
- (72) **Inventors; and**
- (71) **Applicants:** ROTHSTEIN, Jay [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US).

SEREGIN, Sergey [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). KUTA, Anna [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). HUANG, Xin [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). BELL, Kierstin [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). SCHWERTNER, Nicholas [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). CARRIERE, Catherine [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). DAY, Maria [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). UZHACHENKO, Roman [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US). CHILAMARI, Maheshwerreddy [US/US]; 1 Medical Center Drive, HB7937, Lebanon, New Hampshire 03756 (US).

(74) **Agent:** TESKIN, Robin, L.; BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, P.C., Intel-

(54) **Title:** ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF

FIG. 1




Figure 1. Immunologically relevant siRNAs and ASO payloads have been identified and tested. K562-VISTA cells were transfected with 200 nM siRNA (or ASO) alone, and target knockdown was analyzed by qRT-PCR using the ddct method and reported as fold over control. Scrambled siRNA or ASO controls were also ordered from IDT. Payloads marked with (*) were selected for conjugation to a delivery vehicle (anti-VISTA Mab INX201).

(57) **Abstract:** The present invention relates to anti-VISTA antibody RNA or nucleic acid conjugates (ARCs or ANCs) which specifically deliver at least one nucleic acid, e.g., RNAs into immune cells and the use of such ARCs or ANCs as therapeutics, e.g., for treating autoimmune, allergic and inflammatory conditions, or for treating cancer and/or for treating inflammatory symptoms associated therewith elicited by specific immune cell types which express VISTA.

[Continued on next page]

lectual Property Department, 901 K Street, NW, Suite 900,
Washington, District of Columbia 20001 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))